Johnson & Johnson’s new diabetes drug linked to coma and death


'Series of side effects plague common diabetes drug, yet it remained on the market

On Dec. 4, 2015, the FDA forced Johnson & Johnson and other manufacturers of SGLT2 inhibitors to warn consumers via labeling that the drugs may cause ketoacidosis, a serious condition that can cause diabetic comas and death, according to the American Diabetes Association.'


No comments:

Post a Comment